當(dāng)代生物醫(yī)學(xué)研究正處于一個(gè)時(shí)代的門檻，在這個(gè)時(shí)代，生理和病理過(guò)程可以用越來(lái)越精確和機(jī)械的術(shù)語(yǔ)來(lái)分析。生物學(xué)從一門以描述性為主的現(xiàn)象學(xué)學(xué)科，轉(zhuǎn)變?yōu)橐婚T可理解和可預(yù)測(cè)地操縱調(diào)控原則的學(xué)科，為癌癥研究和尋找這種疾病的有效治療方式帶來(lái)了一個(gè)新的維度。癌癥和轉(zhuǎn)移綜述為這些具有挑戰(zhàn)性的進(jìn)展提供了一個(gè)批判性綜述和討論的論壇。每一期的《癌癥與轉(zhuǎn)移評(píng)論》都有一個(gè)特定的主題或主題，并將包含5到7個(gè)不同的貢獻(xiàn)。此外，一個(gè)介紹性前言包括從一個(gè)人誰(shuí)是在該領(lǐng)域的杰出覆蓋。主題和供稿人是由總編與編輯咨詢委員會(huì)的不同成員協(xié)商后選定的。特別強(qiáng)調(diào)與癌癥轉(zhuǎn)移和腫瘤進(jìn)展的分子和細(xì)胞生物學(xué)以及轉(zhuǎn)移性疾病的治療有關(guān)的主題。偶爾的問(wèn)題將致力于對(duì)一種特定類型的癌癥進(jìn)行深入的臨床和生物學(xué)分析。該雜志的一項(xiàng)主要功能是回顧生物學(xué)和惡性疾病治療方面一些更重要和更有趣的最新進(jìn)展，并強(qiáng)調(diào)新的和有希望的方向，無(wú)論是技術(shù)上還是概念上。我們鼓勵(lì)投稿者回顧他們的個(gè)人作品，并進(jìn)行猜測(cè)。

Contemporary biomedical research is on the threshold of an era in which physiological and pathological processes can be analyzed in increasingly precise and mechanistic terms. The transformation of biology from a largely descriptive phenomenological discipline to one in which the regulatory principles can be understood and manipulated with predictability brings a new dimension to the study of cancer and the search for effective therapeutic modalities for this disease. Cancer and Metastasis Reviews provides a forum for critical review and discussion of these challenging developments. Each issue of Cancer and Metastasis Reviews is devoted to a particular theme or topic and will contain from five to seven different contributions. In addition an introductory preface is included from an individual who is distinguished in the field to be covered. The topics and contributors are chosen by the Editor-in-Chief after consultation with various members of the Editorial Advisory Board. Special emphasis is placed on subjects which are of relevance to the molecular and cellular biology of cancer metastasis and tumor progression as well as to the treatment of metastatic disease. Occasional issues will be devoted to an in-depth clinical and biological analysis of a particular type of cancer. A major function of the journal is to review some of the more important and interesting recent developments in the biology and treatment of malignant disease as well as to highlight new and promising directions be they technological or conceptual. Contributors are encouraged to review their personal work and be speculative.